Sign In
Last checked at 
26 Jan 2023 07:00
26 January 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Β
US$ 7 million multi-year enterprise engagements for subscription data services
Β
Validating the Group's strategy and platform technology investments to date
Β
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce two enterprise-level, multi-disease data engagements, with two top 10 global pharmaceutical companies. Combined, the contracts will deliver a cumulative value of US$ 7 million over a two year period, demonstrating Diaceutics' continued successful transition to a subscription based model and further validating the Group's strategy and platform technology investments to date.
Β
Diaceutics will deliver a number of subscription data services to help these global pharmaceutical organisations commercialise their therapeutic treatments more quickly, accurately and efficiently, increasing the uptake by eligible patients and enhancing the organisations' return on R&D investment.
The subscription data services, delivered via Diaceutics' proprietary DXRX platform, include the following products:
Β
Β· | Signal, which uses real-world data through DXRX's network of labs to identify patients who have tested positively for a particular biomarker and are therefore suitable for certain precision medicines; Β |
Β· | Lab Mapping, which provides an in-depth analysis of the lab environment to determine key factors in commercialising the precision medicine; Β |
Β· | Physician Mapping, which examines physician testing behaviour to determine testing rates - a leading indicator for prescription - and the critical physician-to-lab relationship; and Β |
Β· | Disease Testing Rate Tracker, which delivers an accurate view of testing rates, adoption and trends over time. |
Β
Diaceutics has also developed an innovative suite of commercialisation solutions and advisory services, which can be delivered through its proprietary DXRX platform, and offer additional opportunities to expand the scale and coverage of these customer engagements.
Peter Keeling, Chief Executive Officer of Diaceutics, said:
"These enterprise level engagements are a testament to the value placed in our expanding offerings by pharmaceutical and life science organisations.
The continued strong pipeline build serves to highlight the scale of the opportunity available to us within the market, as we continue to further embed within existing customers and onboard new top pharma companies to the DXRX platform.
Looking ahead, our position as a trusted precision medicine partner grants us a unique opportunity to expand our offerings beyond initial data insights and into our full suite of commercialisation solutions and advisory services."
Β
Β
Enquiries:
Β Diaceutics PLCΒ | |
Peter Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer | Via Alma PRΒ |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Stewart Wallace | |
Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Kieran Breheny | |
Matthew Young |
About Diaceutics
Β
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
Β
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
Β
Follow the stocks
